(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release →
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?
Load more...
